Cardinal Health Rating Cut – Contributor Downgrades on 2026E View (CAH)

A Seeking Alpha contributor who sold Cardinal Health in 2024 has issued a rating downgrade, citing a revised outlook for fiscal 2026. The analyst said the stock’s risk-reward profile has shifted, though the article did not detail specific earnings or valuation targets. The move adds to a cautious tone around the healthcare distributor that has been building since mid-2024.

Cardinal Health shares have been under pressure from pharmacy‑margin compression, generic drug pricing headwinds, and a slower‑than‑expected recovery in its medical‑supply segment. The contributor’s 2026E downgrade suggests those structural issues may persist longer than the market had priced. Management’s own guidance for the current fiscal year, provided in August, pointed to adjusted operating earnings per share of $7.30 to $7.55, implying modest year‑over‑year growth but well below the double‑digit expansion some investors had hoped for.

AlphaScala’s proprietary model assigns CAH an Alpha Score of 58 out of 100, with a “Moderate” label. That reading places the stock below the median of the healthcare sector, indicating that the fundamental setup is neutral but tilted toward risk rather than reward. The score reflects a blend of valuation, earnings momentum, and balance‑sheet quality – none of which currently present a clear catalyst for re‑rating.

The downgrade’s timing coincides with a seasonally quiet period for Cardinal Health. No major contract renewals or regulatory decisions are due before the next quarterly report in February, leaving the stock exposed to broader market sentiment and potential sell‑side estimate revisions. If other analysts follow the contributor’s lead, the consensus earnings per share estimate for fiscal 2026 – currently $7.80 according to Bloomberg – could drift lower, further weighing on the multiple.

What would reduce the risk? A strong second‑quarter print in February that reverses the margin trend, or a new customer‑win announcement in the specialty pharmaceutical distribution channel. What would amplify it? A guidance cut in the upcoming fiscal‑first‑quarter filing or a negative read‑across from peers such as McKesson and Cencora when they report later in the month.

For investors tracking the name, the CAH stock page offers a real‑time Alpha Score and the latest contributor ratings. The next hard catalyst is the fiscal first‑quarter earnings release, expected in early November. Until then, the downgrade hangs over the stock.